Genentech Says FDA Approves Venclexta Plus Gazyva for Chronic Lymphocytic Leukemia

Date : 05/15/2019 @ 8:30PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 33.93  0.24 (0.71%) @ 9:00PM
Roche Holding (QX) share price Chart

Genentech Says FDA Approves Venclexta Plus Gazyva for Chronic Lymphocytic Leukemia

Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart

3 Months : From Apr 2019 to Jul 2019

Click Here for more Roche Holding (QX) Charts.

By Michael Dabaie


Roche Group's (RHHBY) Genentech said the U.S. Food and Drug Administration approved Venclexta in combination with Gazyva for the treatment of people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Venclexta is being developed by AbbVie Inc. (ABBV) and Genentech.

The approval is based on the results of the randomized Phase III CLL14 study. Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced the risk of disease progression or death by 67% compared to a current standard of care, Genentech said.


Write to Michael Dabaie at


(END) Dow Jones Newswires

May 15, 2019 15:15 ET (19:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190724 04:18:32